MANAGEMENT OF ASCITES IN PATIENTS OF LIVER CIRRHOSIS

Deepak N Amarapurkar
Consultant Gastroenterologist, Bombay Hospital and Medical Research Centre, Mumbai.


Ascites is a common complication in patients of liver cirrhosis. Almost 50% of patients with cirrhosis will develop ascites over a period of 10 years. Development of ascites also indicates diminished survival. Fifty per cent of patients who develop ascites die over a period of 2 years. [1]
In the last decade there has been tremendous improvement in understanding pathogenesis, diagnosis and management of ascites. In this review I will concentrate on current trends in management of cirrhotic ascites.

Pathogenesis :- Over the years pathogenesis of ascites in cirrhosis was discussed on the basis of underfilling therapy, overflow hypothesis and hypoalbuminaemia. But currently there is general agreement that initial event of renal dysfunction and ascites formation in cirrhosis is combination of increased sinusoidal pressure and hepatic insuffiency. This is based on observations showing higher sinusoidal pressure and more impaired liver function in cirrhotic patients with ascites compared with those patients of cirrhosis who never had ascites. [2] Presently ascites formation is explained on the basis of "peripheral arterial vasodilatation hypothesis", proposed in 1988. [3] According to this hypothesis splanchnic arteriolar vasodilatation secondary to portal hypertension is the initial event. This is followed by baro receptor mediated activation of renin angiotensin system, Sympathetic nervous system and ADH because of the underfilling of arterial vascular compartment not because the circulating blood volume is decreased but because arterial vascular compartment is disproportionally enlarged. Finally this leads to renal sodium and water retention. Splanchnic arterial vasodilation also play a role in increased microvascular hydrostatic pressure and therefore passage of fluid from intravascular compartment to interstitial space during portal hypertension leading to ascites formation. [4]

Diagnosis of ascites :- Moderate to tense ascites can be diagnosed with reasonably high accuracy just by clinical examination and demonstrating shifting dullness or fluid thrill. But in minimal ascites accuracy of physical examination drops down to 50%. Ultrasonography is 100% accurate in detecting free fluid as less as 50 to 100 ml. in peritoneal cavity. [5] CT scan and peritoneoscopy are also equally accurate but are rarely needed to detect ascites. Diagnostic paracentesis is mandatory in diagnosis of ascites. Diagnostic paracentesis especially with ultrasonography guidance is easy and safe. There is 1% risk of abdominal wall haematoma. With USG guidance risk of perforation of viscera is close to nil. Presence of coagulopathy, (abnormal prothrombin time) doesnot preclude paracentesis. Prophylactic infusion of fresh frozen plasma or platelets before paracentesis are not necessary and carry a finite risk of post transfusion hepatitis. [6] Ascitic fluid should be subjected to estimation of cell count and cytology, albumin content, for culture in blood culture bottles. [7] Estimation of serum albumin simultaneously should be carried out. When diagnosis of tuberculosis is suspected estimation of ascitic fluid adenosine deaminase is required. [8]
Ascitic fluid is classified as "transudate" or exudate depending upon specific gravity, protein content and cell count. Fluid containing more than 3g% of protein and 200 cells/mm3 and specific gravity 1015 were termed as exudate and those with lower values were termed as transudates. This system of classification has been shown to be faulty and unreliable.
There is significant overlap between transudates and exudates and almost 1/4 patients can not be categorized.
[9,10] Hence serum-ascites albumin gradient is calculated by subtracting the albumin concentration of ascitic fluid albumin from the albumin concentration of serum obtained on the same day. The serum - ascites albumin gradient (SAAG) correlates directly with portal hypertension. Patients with gradients of ô 1.1 g/dL have portal hypertension and patient with gradients of 1.1 g/dL do not. The accuracy of SAAG is 97%. Hence ascites should not be classified as exudate or transudate but should be classified on SAAG more than 1.1 g/dL (portal hypertension related) and less than 1.1 g/dL (nonportal hypertension related). [9] Further characterizations can be done on the basis of cell count, malignant cells, culture or ascitic fluid ADA levels.
Spontaneous bacterial peritonitis (SBP) is a frequent complication in patients of cirrhotic ascites and is seen in 1/3 of patients at admission.
[10,11] Some of these patients do not have signs and symptoms of peritonitis. Hence bedside inoculation of ascitic fluid in blood culture bottles is essential in every case of cirrhotic ascites. In patients of SBP bacterial load the fluid being very low sending the fluid to laboratory and culturing it after few hours invariably gives poor results. [10,11]
Ascitic fluid adenosine adeaminase estimation has been shown to be highly accurate in diagnosis of tuberculous peritonitis hence should be ordered when tuberculosis is suspected.
[8] Minority of patients with cirrhotic ascites have superadded tuberculous peritonitis. [10]
Ultrasonography and CT scanning are useful in detecting intra abdominal masses and other associated findings. But in case of difficult situation when all these modalities fail to give appropriate diagnosis, peritoneoscopy is investigation of choice which is safe and accurate investigations giving histological diagnosis.
[10]
Treatment of ascites :- Patients with mild to moderate ascites with corrected diagnosis based on the ascitic fluid analysis can be treated on out patient basis. Hospitalization is required in patients with tense ascites, presence of other complications, careful monitoring of renal function and when accurate diagnosis is not established.
[1]
Patients with mild to moderate ascites are treated with Sodium restriction of 88 meq/day and fluid restriction 1.2 to 1.5 litres/day depending on serum Na+ levels. Sr. Na+ < 120 meq/litres warrants fluid restriction. Patient should be weighed daily and strict intake and output chart should be maintained. Though formerly it was advised to observe the patients only on fluid and water restriction and expect natriuresis to occur, it has been seen that natriuresis is very rarely seen on expectant treatment hence diuretic therapy should be started immediately.
[13] Ideally using aldesteron antagonist first and then introducing frusemide if required was the policy, it is more practical and economical to use combination of aldesteron antagonist and frusemide since beginning. In patients with odema of feet associated with ascites daily wt loss upto 1 kg is acceptable while in patients without peripheral oedema, a loss of 500 gm/day should be achieved.
Diuretic dosages can be adjusted accordingly. A typical starting daily dose of 100 mg spironolactone and 40 mg of frusemide given once in the morning is used.
[14,15] Though 400 mg of spironolactone and 160 mg of frusemide have been shown to be safe upper limit; It is wise to increase diuretic dosage stepwise with strict check on renal function. Any rise in serum creatinine or blood urea nitrogen should warrant reduction in dosage of diuretics or stoppage of diuretics. Therapeutic paracentesis is treatment of choice for diuretic resistant ascites, but can be offered as primary therapy in patients with tense ascites. In patients of ascites with peripheral oedema tapping 8 to 10 litres of ascitic fluid is safe while in patients without oedema 5 to 6 litres of fluid can be removed safely. [16] In patients with peripheral oedema. I.V. replacement of albumin may not be required.
Generally 75% of fluid protein is replaced by intravenous albumin infusion. Albumin being very expensive, replacement with cheaper agents like dextran and haemaccele have been shown to be safe and effective. Patients treated with paracentesis need to observe salt and water restriction and use diuretic to avoid recurrence of ascites. Therapeutic paracentensis is safe, effective and reduces hospital stay. When treated with volume replacement has significantly less complication rates as compared to diuretic therapy.
[17]
Patients treated with potassium sparing diurectics take spironolactone or ameloride should be instructed to avoid potassium supplements and potassium rich foods like coconut water, banana and fruitjuices. Use of intravenous frusemide which leads to sudden fall in GFR should be avoided in patients of ascites and prostaglandin inhibitors like Nonsteroidal anti inflammatory drugs should be avoided as they can induce azotaemia.
Medical management including therapeutic paracentesis is effective in almost 95% patients of cirrhotic ascites. Refractory ascites is defined as ascites that can not be mobilized or the early recurrence after paracentesis cannot be satisfactorily prevented by medical therapy.
[18] Treatment options for refractory ascites includes peritoneovenous shunt, transjugular intra hepatic portosystemic shunts, extra corporeal ultrafiltration of ascitic fluid with reinfusion and liver transplantation. Novel pharmacological approaches under investigations include use of angiotensin converting enzyme inhibitors, prostaglandins, ornipressin.
Early detection of SBP and its appropriate treatment with antibiotics is also integral part of management of ascites. Use of antibiotics like norfloxacin or Sulphamethoxazole trimethoprim combination for prophylaxis against SBP have been shown to effective may be considered as a part of treatment of ascites.
[19]

REFERENCES

  1. Runyon BA. Care of patients with ascites. N Engl J Med 1994; 330 : 337-42.
  2. Bosch J, Arroyo V, Betriu A, et al. Hepatic hemodynamics and renin angiotensin-aldosteron system in cirrhosis. Gastroenterology 1980; 78 : 92-99.
  3. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arteriolar vasodilatation hypothesis: a proposal for the renal sodium and water retention in cirrhosis. Hepatology 1988; 8 : 1151-57.
  4. Arroyo V, Gines P. Arteriolar vasodilatation and the pathogenesis of the hyperdynamic circulation and renal Sodium and Water retention in cirrhosis. Gastroenterology 1992; 102 : 1077-79.
  5. Goldberg BB, Goodman GA, Clearfield HR. Evaluation of ascites by ultrasound. Radiology 1970; 96 : 15-22.
  6. Runyon BA. Paracentesis of ascitic fluid a safe procedure. Arch Intern Med 1986; 146 : 2259-61.
  7. Runyon BA. Paracentesis and ascitic fluid analysis. In Yamada T, Alpers D, Owyang C, Powell D, Silvestein F, Eds Text book of gastroenterology New York. JB Lippincot 1991; 2455-65.
  8. Marshall JB. Gastrointestinal tuberculosis. Am J Gastroenterol 1993; 88 : 989-99.
  9. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The Serum-ascites albumin gradient is superior to the exudate-transudate concept in differential diagnosis of ascites. Ann Inter Med 1992; 117 : 215-20.
  10. Amarapurkar DN, Kalro RH, Desai HG. Peritoneoscopy in diagnosis of ascites. JAPI 1991; 39 : 933-35.
  11. Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology 1988; 95 : 1351-5.
  12. Amarapurkar DN, Parikh SS, Vishwanath N, Kalro RH, Desai HG. Incidence of spontaneous bacterial peritonitis. JAPI 1992; 11 : 47-8.
  13. Gatta A, Angeli P, Caregaro L, Menon F, Sacerdoti D, Merkel C. A pathophysiological interpretation of unresponsiveness to spironolecton in a stepped care approach to diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology 1991; 14 : 231-6.
  14. Sungaila I, Bartle WR, Walker SE, et al.. Spironolactone pharmakokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology 1992; 102 : 1680-5.
  15. Parikh SS, Desai HG, Kalro RH, Amarapurkar DN. Effectiveness of combination of spironolactone and furosamide in cirrhosis of liver with ascites. Indian Practioner 1989; 52 : 439-43.
  16. Gines P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites: results of randomized study. Gastroenterology 1987; 93 : 243-41.
  17. Arroyo V, Epstein M, Callus G, Gentilini P, Ring-Larsen H, Salerno F. Refractory ascites in cirrhosis: mechanism and treatment. Gastroenterol Int 1989; 2 : 195-207.
  18. Arroyo V, Gines P, Geres AL, et al. Definition and diagnostic criteria of refractory ascites and Hepatorenal Syndrome in Cirrhosis. Hepatology 1996; 23 : 164-76.
  19. Tagle M, Schiff ER. Complications of Cirrhosis. Current Opinions. Gastroenterol 1996; 12 : 300-5.